Biodexa Pharmaceticals Stock Fundamentals
| BDRX Stock | 1.90 0.09 4.52% |
Biodexa Pharmaceticals fundamentals help investors to digest information that contributes to Biodexa Pharmaceticals' financial success or failures. It also enables traders to predict the movement of Biodexa Stock. The fundamental analysis module provides a way to measure Biodexa Pharmaceticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biodexa Pharmaceticals stock.
At this time, Biodexa Pharmaceticals' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 7.6 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 242 K in 2025. Biodexa | Select Account or Indicator |
Biodexa Pharmaceticals Company Current Valuation Analysis
Biodexa Pharmaceticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biodexa Pharmaceticals Current Valuation | (4.73 M) |
Most of Biodexa Pharmaceticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biodexa Pharmaceticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biodexa Pharmaceticals has a Current Valuation of (4.73 Million). This is 100.03% lower than that of the Biotechnology sector and 100.1% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.03% higher than that of the company.
Biodexa Pharmaceticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biodexa Pharmaceticals's current stock value. Our valuation model uses many indicators to compare Biodexa Pharmaceticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biodexa Pharmaceticals competition to find correlations between indicators driving Biodexa Pharmaceticals's intrinsic value. More Info.Biodexa Pharmaceticals is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . At this time, Biodexa Pharmaceticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biodexa Pharmaceticals' earnings, one of the primary drivers of an investment's value.Biodexa Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biodexa Pharmaceticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biodexa Pharmaceticals could also be used in its relative valuation, which is a method of valuing Biodexa Pharmaceticals by comparing valuation metrics of similar companies.Biodexa Pharmaceticals is currently under evaluation in current valuation category among its peers.
Biodexa Pharmaceticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biodexa Pharmaceticals from analyzing Biodexa Pharmaceticals' financial statements. These drivers represent accounts that assess Biodexa Pharmaceticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biodexa Pharmaceticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 293.2M | 312.4M | 80.5M | 1.7M | 1.9M | 1.8M | |
| Enterprise Value | 285.9M | 303.1M | 78.3M | (3.8M) | (4.4M) | (4.2M) |
Biodexa Fundamentals
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (79.31) % | ||||
| Current Valuation | (4.73 M) | ||||
| Shares Outstanding | 668.59 K | ||||
| Shares Owned By Insiders | 8.82 % | ||||
| Shares Owned By Institutions | 29.85 % | ||||
| Number Of Shares Shorted | 46.95 K | ||||
| Price To Book | 0.12 X | ||||
| Price To Sales | 15.31 X | ||||
| Revenue | 381 K | ||||
| Gross Profit | 145 K | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (7.08 M) | ||||
| Total Debt | 464 K | ||||
| Book Value Per Share | 24.07 X | ||||
| Cash Flow From Operations | (6.83 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (77.66) X | ||||
| Target Price | 18.6 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 1.27 M | ||||
| Total Asset | 10.54 M | ||||
| Retained Earnings | (144.77 M) | ||||
| Working Capital | 1.46 M | ||||
| Net Asset | 10.54 M |
About Biodexa Pharmaceticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biodexa Pharmaceticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biodexa Pharmaceticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biodexa Pharmaceticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.1 M | 1.1 M | |
| Total Revenue | 342.9 K | 625.7 K | |
| Cost Of Revenue | 3.7 M | 4.7 M | |
| Stock Based Compensation To Revenue | 0.07 | 0.07 | |
| Sales General And Administrative To Revenue | 13.11 | 9.30 | |
| Research And Ddevelopement To Revenue | 12.28 | 16.57 | |
| Capex To Revenue | 0.79 | 1.18 | |
| Revenue Per Share | 13.87 | 13.18 | |
| Ebit Per Revenue | (18.93) | (19.88) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.